Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis

Experimental Dermatology

Volumn 20, Issue 2, 2011, Pages 107-112

  De Araujo, Elisabeth ^a,b   Dessirier, Valérie ^a,b   Laprée, Geneviève ^b   Valeyrie Allanore, Laurence ^c   Ortonne, Nicolas ^c   Stathopoulos, Efstathios N ^d   Bagot, Martine ^a,b,e   Bensussan, Armand ^a,b,c   Mockenhaupt, Maja ^c,f   Roujeau, Jean Claude ^b,c   Tsapis, Andreas ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITY OF CRETE   (Greece)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Apoptosis; Cytotoxicity; Human; Skin; TNFSF superfamily

Indexed keywords

CD14 ANTIGEN; GAMMA INTERFERON; T6 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLISTER; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; FOLLICULITIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; IN VITRO STUDY; KERATINOCYTE; LYMPHOCYTE; PROTEIN SECRETION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ANTIGENS, CD1; ANTIGENS, CD14; APOPTOSIS; BIOPSY; BLISTER; CASE-CONTROL STUDIES; CELL LINE; CELL PROLIFERATION; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; INTERFERON-GAMMA; KERATINOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 78751698227     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2010.01176.x     Document Type: Article

References (55)

1. Paul C, Wolkenstein P, Adle H et al. Br J Dermatol 1996: 134: 710-714.
2. Viard I, Wehrli P, Bullani R et al. Science 1998: 282: 490-493.
3. Paquet P, Pierard G E. Int J Mol Med 2007: 19: 3-10.
4. Roujeau J C, Kelly J P, Naldi L et al. N Engl J Med 1995: 333: 1600-1607.
5. Mockenhaupt M, Viboud C, Dunant A et al. J Invest Dermatol 2008: 128: 35-44.
6. Correia O, Delgado L, Ramos J P et al. Arch Dermatol 1993: 129: 466-468.
7. Le Cleach L, Delaire S, Boumsell L et al. Clin Exp Immunol 2000: 119: 225-230.
8. Nassif A, Bensussan A, Dorothee G et al. J Invest Dermatol 2002: 118: 728-733.
9. Nassif A, Bensussan A, Boumsell L et al. J Allergy Clin Immunol 2004: 114: 1209-1215.
10. Chung W H, Hung S I, Yang J Y et al. Nat Med 2008: 14: 1343-1350.
11. Chave T A, Mortimer N J, Sladden M J et al. Br J Dermatol 2005: 153: 241-253.
12. Miyauchi H, Hosokawa H, Akaeda T et al. Arch Dermatol 1991: 127: 851-855.
13. Villada G, Roujeau J C, Clerici T et al. Arch Dermatol 1992: 128: 50-53.
14. Schnyder B, Burkhart C, Schnyder-Frutig K et al. J Immunol 2000: 164: 6647-6654.
15. Paquet P, Nikkels A, Arrese J E et al. Arch Dermatol 1994: 130: 605-608.
16. Paquet P, Pierard G E. Int J Mol Med 1998: 1: 459-462.
17. Wolkenstein P, Latarjet J, Roujeau J C et al. Lancet 1998: 352: 1586-1589.
18. Abe R, Shimizu T, Shibaki A et al. Am J Pathol 2003: 162: 1515-1520.
19. Boukamp P, Petrussevska R T, Breitkreutz D et al. J Cell Biol 1988: 106: 761-771.
20. Hansen M B, Nielsen S E, Berg K. J Immunol Methods 1989: 119: 203-210.
21. Nassif A, Moslehi H, Le Gouvello S et al. J Invest Dermatol 2004: 123: 850-855.
22. Leverkus M, Sprick M R, Wachter T et al. J Invest Dermatol 2003: 121: 149-155.
23. Grando S A, Bystryn J C, Chernyavsky A I et al. Exp Dermatol 2009: 18: 764-770.
24. Kerstan A, Leverkus M, Trautmann A. Exp Dermatol 2009: 18: 893-899.
25. Raj D, Brash D E, Grossman D. J Invest Dermatol 2006: 126: 243-257.
26. Lin J, Liu X, Bao Y et al. Exp Dermatol 2008: 17: 530-536.
27. Stur K, Karlhofer F M, Stingl G. J Invest Dermatol 2007: 127: 802-807.
28. Daehn I S, Varelias A, Rayner T E. Exp Dermatol 2010: 19: 372-380.
29. Ueta M, Sotozono C, Inatomi T et al. Br J Ophthalmol 2008: 92: 989-991.
30. Verneuil L, Ratajczak P, Allabert C et al. Br J Dermatol 2009: 161: 1371-1375.
31. Banno T, Gazel A, Blumenberg M. J Biol Chem 2004: 279: 32633-32642.
32. Murata J, Abe R. J Invest Dermatol 2007: 127: 744-745.
33. Leverkus M, Neumann M, Mengling T et al. Cancer Res 2000: 60: 553-559.
34. Qin J Z, Bacon P, Chaturvedi V et al. J Invest Dermatol 2001: 117: 898-907.
35. Wachter T, Sprick M, Hausmann D et al.J Biol Chem 2004: 279: 52824-52834.
36. Chaturvedi V, Bodner B, Qin J Z et al. J Dermatol Sci 2006: 41: 31-41.
37. Konur A, Schulz U, Eissner G et al. Br J Dermatol 2005: 152: 1134-1142.
38. Mirandola P, Ponti C, Gobbi G et al. Blood 2004: 104: 2418-2424.
39. Obata-Onai A, Hashimoto S, Onai N et al. Int Immunol 2002: 14: 1085-1098.
40. Zamai L, Ahmad M, Bennett I M et al. J Exp Med 1998: 188: 2375-2380.
41. Symington F W. J Invest Dermatol 1989: 92: 798-805.
42. Smyth M J, Cretney E, Takeda K et al. J Exp Med 2001: 193: 661-670.
43. Jo M, Kim T H, Seol D W et al. Nat Med 2000: 6: 564-567.
44. Wilson C A, Browning J L. Cell Death Differ 2002: 9: 1321-1333.
45. Nakayama M, Ishidoh K, Kojima Y et al. J Immunol 2003: 170: 341-348.
46. Nathan C F, Murray H W, Wiebe M E et al. J Exp Med 1983: 158: 670-689.
47. Griffith T S, Wiley S R, Kubin M Z et al. J Exp Med 1999: 189: 1343-1354.
48. Fanger N A, Maliszewski C R, Schooley K et al. J Exp Med 1999: 190: 1155-1164.
49. Paquet P, Ribbens C, Pierard G E. Clin Exp Dermatol 2007: 32: 728-732.
50. Schmidt E, Ambach A, Bastian B et al. J Am Acad Dermatol 1996: 34: 310-312.
51. Santamaria Babi L F, Moser B, Perez Soler M T et al. Eur J Immunol 1996: 26: 2056-2061.
52. Garcia-Doval I, LeCleach L, Bocquet H et al. Arch Dermatol 2000: 136: 323-327.
53. Paquet P, Pierard G E. Dermatology 1999: 198: 198-202.
54. Mizukawa Y, Yamazaki Y, Shiohara T. Br J Dermatol 2008: 158: 1230-1238.
55. Takahashi R, Kano Y, Yamazaki Y et al. J Immunol 2009: 182: 8071-8079.